狄诺塞麦的使用说明

Instructions for Use: Denosumab is indicated for the treatment of osteoporosis, therapy-induced bone loss, metastasis to bone, and giant cell tumor of bone. Denosumab can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. Inject 120 mg subcutaneously into the upper arm, upper thigh, or abdomen every 4 weeks to give calcium and vitamin D when needed to treat or prevent hypocalcemia. Disabled for those with allergic reactions.

Hypocalcemia must be corrected before denosumab therapy can be initiated. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to such patients. Physicians should evaluate the need for continued denosumab treatment in patients who develop serious infections while taking denosumab.

Osteonecrosis of the jaw often occurs with tooth extraction and local infection that delays healing. A routine oral examination should be performed before starting denosumab treatment, and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time.

The most common adverse reactions (incidence greater than or equal to 25% of patients) in patients receiving denosumab were fatigue/asthenia, hypophosphatemia, and nausea. If a serious adverse reaction occurs, the patient should contact and inform the doctor as soon as possible and do not take the medicine privately.

The above are the instructions for use. If you have other questions, you can consult the medical companion passenger service for other relevant information.